A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, multi-center, dose-ranging study to characterize the safety,
tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered
weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or
refractory Cutaneous T-cell Lymphoma (CTCL).